– USA, FL – Gemini BioProducts Holding, Inc., today announced the appointment of Cory Stevenson to its Board of Directors.
Gemini is a portfolio company of Health Investment Partners, LLC, a Florida-based healthcare private equity firm, based in Fort Lauderdale.
About Cory Stevenson
Mr. Stevenson retired in 2021 from Thermo Fisher Scientific (NYSE: TMO), where he served as the President of the BioProduction Division. Thermo Fisher Scientific is the world’s leader in serving science and its BioProduction business produces many of the industry’s leading products and technologies. During Cory’s tenure, the business grew revenues from $200 million to over $2.5 billion annually. Before serving as President of the BioProduction Division, Cory served as Group President of Pelican Life Sciences, VP and General Manager of Oncology Pharmaceutical Services at US Oncology, President of Fisher Healthcare, a Fisher Scientific division and various positions at Baxter International.
About GeminiBio
Founded in 1985, GeminiBio serves the global biotechnology industry, from basic research to commercial production, with a focus on helping our customers accelerate the development of life-enhancing biotherapeutics by streamlining and improving their cell culture and process liquid manufacturing workflows. The company’s products are organized into two core verticals – Cell Culture Solutions and Process Liquid Solutions. Located in West Sacramento, California, GeminiBio has 57,000 square feet of cGMP manufacturing space that is segregated between animal-origin-free and animal-component manufacturing. GeminiBio is an ISO 13485 certified, FDA registered Class 1 Medical Device Manufacturer, aligned with 21 CFR Part 820.
For more information: https://www.geminibio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.